Unity Subcutaneous Infusion System for Remodulin
Infusion Pump, Drug Specific, Pharmacy-Filled. 510(k) K191313, from DEKA Research & Development (Manchester, NH). Product code QJY, class 2.
As of Nov 20, 2026, K191313 is an FDA 510(k) held by DEKA Research & Development, substantially equivalent on Feb 21, 2020 after 282 days, with no recalls tied to it in FDA's recall database.
- Review time: 282 days
- Recalls: 0
- Cited as a predicate by: 2 devices
The Unity Subcutaneous Infusion System (the Unity System) is intended for continuous subcutaneous delivery of Remodulin® (treprostinil) Injection for use in adults (greater than 22 years of age).
- Unity Subcutaneous Delivery System for RemodulinK190182 · DEKA Research & Development · May 6, 2019
- Remunity SystemK243354 · Deka Research & Development Corp. · Nov 27, 2024
- Remunity Pump for Remodulin (treprostinil) InjectionK202690 · Deka Research and Development · Dec 30, 2020
- Remunity SystemK243354 · Deka Research & Development Corp. · Nov 27, 2024
- Remunity SystemK240256 · Deka Research and Development · Jun 12, 2024
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- May 15, 2019
- Review panel
- General Hospital
- Regulation
- 21 CFR 880.5725
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files